Loss of muscle mass represents a significant risk to oesophageal cancer survival
Oesophageal cancer patients who suffer loss of muscle mass (sarcopenia) during neoadjuvant therapy (chemotherapy prior to surgery) survive, on average, 32 months less than patients with no sarcopenia. This is the central ...
Feb 14, 2017
0
0